rhEGF
Phase 3Small molecule
Daewoong Pharmaceutical Co. LTD.rhEGF is one of 66 small molecule programs targeting Diabetic Foot. It is currently in Phase 3.
2
Indications
4
Total Trials
0
Active Trials
65
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
210 competitors in Diabetic Foot
#DrugCompanyPhaseTrials
1Isordil
AstraZenecaPhase 3
Zyvox
PfizerPhase 3
Cysteine Hydrochloride
NovartisPhase 3
Invanz
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Tygacil
PPrism Pharmaceuticals
Phase 3
Cubicin
BBaxter Healthcare Corporation
Phase 3
Urokinase
Mmedac GmbH
Phase 3
Bemiparin
RRovi Pharmaceuticals Laboratories
Phase 3
Biochaperone Combo
AAdocia
Phase 3
Beta-Glucan
BBiotec Pharmacon ASA
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Efficacy and Safety1 trial
Gingival Recession1 trial
Oral Mucositis1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for rhEGF. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details